NCT04098133 Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital
| NCT ID | NCT04098133 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Infections With CPB |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-08-22 |
| Primary Completion | 2029-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2019-08-22 with a primary completion date of 2029-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.
Eligibility Criteria
Inclusion Criteria: * Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028 Exclusion Criteria: * Patients with documented refusal of subsequent use of their data
Contact & Investigator
Sarah Tschudin Sutter, Prof. Dr. MD
PRINCIPAL INVESTIGATOR
University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology
Frequently Asked Questions
Who can join the NCT04098133 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Infections With CPB. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04098133 currently recruiting?
Yes, NCT04098133 is actively recruiting participants. Contact the research team at sarah.tschudin@usb.ch for enrollment information.
Where is the NCT04098133 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT04098133 clinical trial?
NCT04098133 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Sarah Tschudin Sutter, Prof. Dr. MD at University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology. The trial plans to enroll 100 participants.